OncoHost

High-Level Overview

OncoHost is a precision oncology technology company developing PROphet®, an AI-powered, plasma-based proteomic platform that analyzes ~7,000 proteins from a single pre-treatment blood sample to predict clinical benefit from immunotherapies like PD-1/PD-L1 inhibitors.[1][2][3][4][5] It primarily serves oncologists and patients with advanced cancers, such as non-small cell lung cancer (NSCLC), by solving the challenge of identifying responders versus non-responders to immunotherapy, complementing PD-L1 and genomic tests to enable personalized treatment decisions, reduce unnecessary therapies, and improve outcomes like overall survival (OS) and progression-free survival (PFS).[2][3][4][5] The platform has demonstrated strong growth momentum, earning awards like Top Precision Oncology Solution for 2025, Proteomics Innovation of the Year (2025), and multiple Merit Awards, backed by the large-scale PROPHETIC trial (over 1,700 patients across 40 sites).[2][3][5]

Headquartered in Binyamina, Israel, and Cary, North Carolina, OncoHost focuses on shifting precision medicine from tumor-centric to host biology-centric approaches, with expansions into melanoma, HPV-related cancers, and immune-related adverse events (irAEs) prediction.[1][2][3]

Origin Story

OncoHost emerged from advancements in proteomics and AI to address gaps in immunotherapy response prediction, particularly for NSCLC where traditional biomarkers like PD-L1 fall short.[1][5] The company licensed aptamer-based proteomic technology from SomaLogic to power its platform, enabling analysis of thousands of plasma proteins.[1] Key figure Ofer Sharon, MD, serves as CEO, leading efforts to translate research into clinical tools, as highlighted in interviews on personalized cancer therapy challenges.[1]

Pivotal early traction came from the PROPHETIC trial (NCT04056247), one of the largest prospective cohorts in precision oncology with over 1,700 patients, validating PROphet®'s predictions for clinical benefit, resistance mechanisms, and toxicities.[2][5] This trial, spanning 40 global sites, marked a breakthrough in host-response profiling, propelling OncoHost toward commercialization of PROphetNSCLC™.[2][3][5]

Core Differentiators

• Host-Centric Proteomics: Unlike tumor-focused diagnostics, PROphet® analyzes systemic host response via ~7,000 plasma proteins, capturing tumor microenvironment interplay, inflammation, and immune evasion hallmarks for holistic personalization.[2][3][4][5]
• AI-Powered Predictions: Combines bioinformatics, machine learning, and pattern recognition to deliver a PROphet® score predicting immunotherapy benefit, OS/PFS, adverse events (e.g., irAEs in NSCLC), and mechanisms of action—all from one blood test.[1][2][4][5]
• Clinical Validation and Scalability: Trained on PROPHETIC trial data; indication-agnostic design supports NSCLC initially, with extensions to melanoma, HPV-cancers, autoimmune diseases, and more; complements existing tests without added burden.[2][3][5]
• Physician-Friendly Insights: Provides explainable reports guiding monotherapy vs. chemo-immunotherapy decisions, reducing overtreatment costs and toxicities.[3][4][5]

Role in the Broader Tech Landscape

OncoHost rides the precision oncology wave, fueled by immunotherapy's rise (e.g., checkpoint inhibitors) amid stagnant response rates (~20-40% in NSCLC), where host biology increasingly proves key over tumor genomics alone.[1][2][5] Timing aligns with proteomics maturation (e.g., SomaLogic tech) and AI's role in multi-omics integration, enabling scalable blood-based tests over invasive biopsies.[1][4]

Market forces favor it: surging demand for companion diagnostics amid $100B+ oncology spend, regulatory push for personalized meds, and post-pandemic emphasis on efficient trials via patient stratification.[2][3] OncoHost influences the ecosystem by validating host-response models, inspiring similar AI-proteomics tools, and accelerating drug development through outcome predictions.[4][5]

Quick Take & Future Outlook

OncoHost is poised to expand PROphet® beyond NSCLC into multi-cancer indications (e.g., melanoma, solid tumors) and non-oncology (autoimmune, inflammation), leveraging its trial infrastructure for faster FDA/CE approvals and partnerships.[1][3][4][5] Trends like multi-modal AI (proteomics + genomics) and real-world evidence will amplify its edge, potentially capturing share in the $20B+ companion diagnostics market.

Its influence may evolve from niche predictor to standard-of-care enabler, redefining precision medicine by prioritizing patient biology—echoing its mission to transform outcomes through truly personalized care.[2][3]